1
|
McCaig L, Nowak S, Abbott A, Carhart J, McMahon ME, Debie E, Li H, Maina F, Ji AJ, Fu M, Wu Y, Lennard A, Mazzeo T, Wolfe C, Timpano R, Babayan Y, Gruenig L. Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes. AAPS J 2024; 26:34. [PMID: 38485849 DOI: 10.1208/s12248-024-00903-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 02/27/2024] [Indexed: 03/19/2024] Open
Abstract
ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.
Collapse
Affiliation(s)
- Lori McCaig
- Pfizer Inc, 21823 30Th Drive SE, Bothell, Washington, 98021, USA
| | - Steven Nowak
- AbbVie, 1 N Waukegan Rd. Bldg. AP50; Dept PA71, North Chicago, Illinois, 60064, USA.
| | - Alexander Abbott
- Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, UK
| | - Jenny Carhart
- Takeda Development Center Americas, Inc. 95 Hayden Ave, Lexington, Massachusetts, 02421, USA
| | - Megan E McMahon
- Pfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA
| | - Elke Debie
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium
| | - Hanlin Li
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts, 02210, USA
| | - Francis Maina
- AbbVie, 1401 Sheridan Road, North Chicago, Illinois, 60064, USA
| | - Andrea J Ji
- Genentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA
| | - Mingkun Fu
- Sumitomo Pharma America, 84 Waterford Drive, Marlborough, Massachusetts, 01752, USA
| | - Yan Wu
- Merck & Co, 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA
| | - Andrew Lennard
- Amgen Ltd, 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
| | - Tony Mazzeo
- Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey, 08903, USA
| | - Chad Wolfe
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | - Robert Timpano
- Pfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA
| | - Yelizaveta Babayan
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | - Lars Gruenig
- CSL Behring, CSL Behring AG, Wankdorfstrasse 10, CH-3014, Bern, Switzerland
| |
Collapse
|
2
|
Huelsmeyer M, Kuzman D, Bončina M, Martinez J, Steinbrugger C, Weusten J, Calero-Rubio C, Roche W, Niederhaus B, VanHaelst Y, Hrynyk M, Ballesta P, Achard H, Augusto S, Guillois M, Pszczolinski C, Gerasimov M, Neyra C, Ponduri D, Ramesh S, Clénet D. A universal tool for stability predictions of biotherapeutics, vaccines and in vitro diagnostic products. Sci Rep 2023; 13:10077. [PMID: 37344503 DOI: 10.1038/s41598-023-35870-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 05/25/2023] [Indexed: 06/23/2023] Open
Abstract
It is of particular interest for biopharmaceutical companies developing and distributing fragile biomolecules to warrant the stability and activity of their products during long-term storage and shipment. In accordance with quality by design principles, advanced kinetic modeling (AKM) has been successfully used to predict long-term product shelf-life and relies on data from short-term accelerated stability studies that are used to generate Arrhenius-based kinetic models that can, in turn, be exploited for stability forecasts. The AKM methodology was evaluated through a cross-company perspective on stability modeling for key stability indicating attributes of different types of biotherapeutics, vaccines and biomolecules combined in in vitro diagnostic kits. It is demonstrated that stability predictions up to 3 years for products maintained under recommended storage conditions (2-8 °C) or for products that have experienced temperature excursions outside the cold-chain show excellent agreement with experimental real-time data, thus confirming AKM as a universal and reliable tool for stability predictions for a wide range of product types.
Collapse
Affiliation(s)
- M Huelsmeyer
- Drug Product Development, AbbVie, Ludwigshafen, Germany
| | - D Kuzman
- Biologics Drug Product, Technical R&D, Global Drug Development, Novartis , Mengeš, Slovenia
| | - M Bončina
- Biologics Drug Product, Technical R&D, Global Drug Development, Novartis , Mengeš, Slovenia
| | - J Martinez
- R&D Immunoassays, Biomolecule Engineering - bioMAP, bioMérieux, Marcy L'étoile, France
| | - C Steinbrugger
- R&D Immunoassays, Biomolecule Engineering - bioMAP, bioMérieux, Marcy L'étoile, France
| | - J Weusten
- Center for Mathematical Sciences, MSD, Oss, The Netherlands
| | - C Calero-Rubio
- Biologics Drug Product Development & Manufacturing, Sanofi, Framingham, USA
| | - W Roche
- MSAT, Sanofi, Waterford, Ireland
| | - B Niederhaus
- CMC-Biologics Statistics, Sanofi, Frankfurt, Germany
| | - Y VanHaelst
- CMC-Biologics Statistics, Sanofi, Gent, Germany
| | - M Hrynyk
- Global Drug Product Bioprocess Development, Sanofi, Toronto, Canada
| | - P Ballesta
- Altran Technologies, Capgemini Engineering, Lyon, France
| | - H Achard
- Altran Technologies, Capgemini Engineering, Lyon, France
| | - S Augusto
- Manufacturing Technology Department, Sanofi, Val-de-Reuil, France
| | - M Guillois
- Manufacturing Technology Department, Sanofi, Val-de-Reuil, France
| | - C Pszczolinski
- Manufacturing Technology Department, Sanofi, Val-de-Reuil, France
| | - M Gerasimov
- Manufacturing Technology Department, Sanofi, Swiftwater, USA
| | - C Neyra
- Manufacturing Technology Department, Sanofi, Swiftwater, USA
| | - D Ponduri
- Manufacturing Technology Department, Sanofi, Hyderabad, India
| | - S Ramesh
- Manufacturing Technology Department, Sanofi, Hyderabad, India
| | - D Clénet
- Global Drug Product Bioprocess Development, Sanofi, Marcy L'étoile, France.
| |
Collapse
|
3
|
How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation. Vaccine 2022; 40:1223-1230. [PMID: 35180994 PMCID: PMC8846337 DOI: 10.1016/j.vaccine.2021.12.038] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 11/11/2021] [Accepted: 11/12/2021] [Indexed: 11/22/2022]
Abstract
Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention tool in the public health realm are found languishing in the gap between such innovations and their easy availability/accessibility to vulnerable populations. This paradox has been best highlighted during the unprecedented crisis of the COVID-19 pandemic. As part of a two series publication on the vaccine industry's view on how to accelerate the availability of vaccines worldwide, this paper offers a deep dive into detailed proposals to enable this objective. These first-of-its-kind technical proposals gleaned from challenges and learnings from the COVID-19 pandemic are applicable to vaccines that are already on the market for routine pathogens as well as for production of new(er) vaccines for emerging pathogens with a public health threat potential. The technical proposals offer feasible and sustainable solutions in pivotal areas such as process validation, comparability, stability, post-approval changes, release testing, packaging, genetically modified organisms and variants, which are linked to manufacturing and quality control of vaccines. Ultimately these proposals aim to ease high regulatory complexity and heterogeneity surrounding the manufacturing & distribution of vaccines, by advocating the use of (1) Science and Risk based approaches, (2) global regulatory harmonization, (3) use of reliance, work-sharing, and recognition processes and (4) digitalization. Capitalizing & collaborating on such new-world advancements into the science of vaccines will eventually benefit the world by turning vaccines into vaccination, ensuring the health of everyone.
Collapse
|
4
|
Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling. Pharmaceutics 2022; 14:pharmaceutics14020375. [PMID: 35214107 PMCID: PMC8880208 DOI: 10.3390/pharmaceutics14020375] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/23/2022] [Accepted: 02/04/2022] [Indexed: 12/04/2022] Open
Abstract
A crucial aspect of pharmaceutical development is the demonstration of long-term stability of the drug product. Biopharmaceuticals, such as proteins or peptides in liquid formulation, are typically administered via parental routes and should be stable over the shelf life, which generally includes a storing period (e.g., two years at 5 °C) and optionally an in-use period (e.g., 28 days at 30 °C). Herein, we present a case study where chemical degradation of SAR441255, a therapeutic peptide, in different formulations in combination with primary packaging materials was analyzed under accelerated conditions to derive long-term stability predictions for the recommended storing conditions (two years at 5 °C plus 28 days at 30 °C) using advanced kinetic modeling. These predictions served as a crucial decision parameter for the entry into clinical development. Comparison with analytical data measured under long-term conditions during the subsequent development phase demonstrated a high prediction accuracy. These predictions provided stability insights within weeks that would otherwise take years using measurements under long-term stability conditions only. To our knowledge, such in silico studies on stability predictions of a therapeutic peptide using accelerated chemical degradation data and advanced kinetic modeling with comparisons to subsequently measured real-life long-term stability data have not been described in literature before.
Collapse
|
5
|
Neyra C, Clénet D, Bright M, Kensinger R, Hauser S. Predictive modeling for assessing the long-term thermal stability of a new fully-liquid quadrivalent meningococcal tetanus toxoid conjugated vaccine. Int J Pharm 2021; 609:121143. [PMID: 34600051 DOI: 10.1016/j.ijpharm.2021.121143] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/20/2021] [Accepted: 09/26/2021] [Indexed: 10/20/2022]
Abstract
Establishing product stability is critical for pharmaceuticals. We used a modeling approach to predict the thermal stability of a fully-liquid quadrivalent meningococcal (serogroups A, C, W, Y) conjugate vaccine (MenACYW-TT; MenQuadfi®) at potential transportation and storage temperatures. Vaccine degradation was determined by measuring the rate of hydrolysis through an increase of free polysaccharide (de-conjugated or unconjugated polysaccharide) content during six months storage at 25 °C, 45 °C and 56 °C. A procedure combining advanced kinetics and statistics was used to screen and compare kinetic models describing observed free polysaccharide increase as a function of time and temperature for each serogroup. Statistical analyses were used to quantify prediction accuracy. A two-step kinetic model described the increase in free polysaccharide content for serogroup A; whereas, one-step kinetic models were found suitable to describe the other serogroups. The models were used to predict free polysaccharide increases for each serogroup during long-term storage under recommended conditions (2-8 °C), and during temperature excursions to 25 °C or 40 °C. In both cases, serogroup-specific simulations accurately predict the respective observed experimental data. Experimental data collected to 48 months at 5 °C were within 99% predictive bands. The models described here can be used with confidence to establish shelf-life for this fully-liquid quadrivalent meningococcal conjugate vaccine; as well as, monitor in real-time free polysaccharide increase for vaccines experiencing temperature excursions during shipment/storage.
Collapse
Affiliation(s)
- Christophe Neyra
- Manufacturing Technology Department, Sanofi Pasteur, Swiftwater, PA, USA.
| | - Didier Clénet
- Bioprocess R&D Department, Sanofi Pasteur, Marcy l'Etoile, France.
| | - Marcia Bright
- Quality Control Stability, Sanofi Pasteur, Swiftwater, PA, USA.
| | | | - Steven Hauser
- Manufacturing Technology Department, Sanofi Pasteur, Swiftwater, PA, USA.
| |
Collapse
|
6
|
Clénet D, Clavier L, Strobbe B, Le Bon C, Zoonens M, Saulnier A. Full-length G glycoprotein directly extracted from rabies virus with detergent and then stabilized by amphipols in liquid and freeze-dried forms. Biotechnol Bioeng 2021; 118:4317-4330. [PMID: 34297405 PMCID: PMC9291542 DOI: 10.1002/bit.27900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 06/22/2021] [Accepted: 07/09/2021] [Indexed: 11/11/2022]
Abstract
Pathogen surface antigens are at the forefront of the viral strategy when invading host organisms. These antigens, including membrane proteins (MPs), are broadly targeted by the host immune response. Obtaining these MPs in a soluble and stable form constitutes a real challenge, regardless of the application purposes (e.g. quantification/characterization assays, diagnosis, and preventive and curative strategies). A rapid process to obtain a native-like antigen by solubilization of a full-length MP directly from a pathogen is reported herein. Rabies virus (RABV) was used as a model for this demonstration and its full-length G glycoprotein (RABV-G) was stabilized with amphipathic polymers, named amphipols (APols). The stability of RABV-G trapped in APol A8-35 (RABV-G/A8-35) was evaluated under different stress conditions (temperature, agitation, and light exposure). RABV-G/A8-35 in liquid form exhibited higher unfolding temperature (+6°C) than in detergent and was demonstrated to be antigenically stable over 1 month at 5°C and 25°C. Kinetic modeling of antigenicity data predicted antigenic stability of RABV-G/A8-35 in a solution of up to 1 year at 5°C. The RABV-G/A8-35 complex formulated in an optimized buffer composition and subsequently freeze-dried displayed long-term stability for 2-years at 5, 25, and 37°C. This study reports for the first time that a natural full-length MP extracted from a virus, complexed to APols and subsequently freeze-dried, displayed long-term antigenic stability, without requiring storage under refrigerated conditions.
Collapse
Affiliation(s)
- Didier Clénet
- Bioprocess R&D DepartmentSanofi PasteurMarcy l'EtoileFrance
| | - Léna Clavier
- Bioprocess R&D DepartmentSanofi PasteurMarcy l'EtoileFrance
| | - Benoît Strobbe
- Bioprocess R&D DepartmentSanofi PasteurMarcy l'EtoileFrance
| | - Christel Le Bon
- Laboratoire de Biologie Physico‐Chimique des Protéines Membranaires, CNRS, Institut de Biologie Physico‐ChimiqueUniversité de ParisParisFrance
| | - Manuela Zoonens
- Laboratoire de Biologie Physico‐Chimique des Protéines Membranaires, CNRS, Institut de Biologie Physico‐ChimiqueUniversité de ParisParisFrance
| | - Aure Saulnier
- Bioprocess R&D DepartmentSanofi PasteurMarcy l'EtoileFrance
- Department of Analytical SciencesSanofi PasteurMarcy l'EtoileFrance
| |
Collapse
|
7
|
Campa C, Pronce T, Paludi M, Weusten J, Conway L, Savery J, Richards C, Clénet D. Use of Stability Modeling to Support Accelerated Vaccine Development and Supply. Vaccines (Basel) 2021; 9:vaccines9101114. [PMID: 34696222 PMCID: PMC8539070 DOI: 10.3390/vaccines9101114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 09/23/2021] [Accepted: 09/24/2021] [Indexed: 02/04/2023] Open
Abstract
Stability assessment of pharmaceuticals in specific storage and shipment conditions is a key requirement to ensure that safe and efficacious products are administered to patients. This is particularly relevant for vaccines, with numerous vaccines strictly requiring cold storage to remain stable. When stability evaluation is exclusively based on real-time data, it may represent a bottleneck for rapid and effective vaccine access. Stability modeling for vaccines represents a key resource to predict stability based on accelerated stability studies; nevertheless, this approach is not fully exploited for these kinds of products. This is likely because of the complexity and diversity of vaccines, as well as the limited availability of dedicated guidelines or illustrative case studies. This article reports a cross-company perspective on stability modeling for vaccines. Several examples, based on the direct experience of the contributors, demonstrate that modeling approaches can be highly valuable to predict vaccines’ shelf life and behavior during shipment or manipulation. It is demonstrated that modeling methodologies need to be tailored to the nature of the vaccine, the available prior knowledge, and the monitored attributes. Considering that the well-established strategies reported in ICH or WHO guidelines are not always broadly applicable to vaccines, this article represents an important source of information for vaccine researchers and manufacturers, setting the grounds for further discussion within the vaccine industry and with regulators.
Collapse
Affiliation(s)
| | | | | | - Jos Weusten
- MSD, Center for Mathematical Sciences, 5344 Oss, The Netherlands;
| | - Laura Conway
- Merck, Regulatory Affairs CMC Vaccines, North Wales, PA 19454, USA;
| | - James Savery
- AstraZeneca, Data Science & Modeling, BioPharmaceuticals Development, R&D, Cambridge 01223, UK;
| | | | - Didier Clénet
- Sanofi-Pasteur, Bioprocess R&D Department, 69280 Marcy l’Etoile, France
- Correspondence:
| |
Collapse
|
8
|
Azam JM, Saitta B, Bonner K, Ferrari MJ, Pulliam JRC. Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response. Vaccine 2021; 39:5845-5853. [PMID: 34481696 DOI: 10.1016/j.vaccine.2021.08.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 07/30/2021] [Accepted: 08/13/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Rapid outbreak response vaccination is a strategy for measles control and elimination. Measles vaccines must be stored and transported within a specified temperature range, but this can present significant challenges when targeting remote populations. Measles vaccine licensure for delivery outside cold chain (OCC) could provide more vaccine transport/storage space without ice packs, and a solution to shorten response times. However, due to vaccine safety and wastage considerations, the OCC strategy will require other operational changes, potentially including the use of 1-dose (monodose) instead of 10-dose vials, requiring larger transport/storage equipment currently achieved with 10-dose vials. These trade-offs require quantitative comparisons of vaccine delivery options to evaluate their relative benefits. METHODS We developed a modelling framework combining elements of the vaccine supply chain - cold chain, vial, team, and transport equipment types - with a measles transmission dynamics model to compare vaccine delivery options. We compared 10 strategies resulting from combinations of the vaccine supply elements and grouped into three main classes: OCC, partial cold chain (PCC), and full cold chain (FCC). For each strategy, we explored a campaign with 20 teams sequentially targeting 5 locations with 100,000 individuals each. We characterised the time needed to freeze ice packs and complete the campaign (campaign duration), vaccination coverage, and cases averted, assuming a fixed pre-deployment delay before campaign commencement. We performed sensitivity analyses of the pre-deployment delay, population sizes, and two team allocation schemes. RESULTS The OCC, PCC, and FCC strategies achieve campaign durations of 50, 51, and 52 days, respectively. Nine of the ten strategies can achieve a vaccination coverage of 80%, and OCC averts the most cases. DISCUSSION The OCC strategy, therefore, presents improved operational and epidemiological outcomes relative to current practice and the other options considered.
Collapse
Affiliation(s)
- James M Azam
- DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa.
| | - Barbara Saitta
- Access Campaign, Médecins Sans Frontières, New York, United States
| | - Kimberly Bonner
- University of Minnesota, Twin Cities, Minneapolis, United States
| | - Matthew J Ferrari
- The Center for Infectious Disease Dynamics, The Pennsylvania State University, PA, United States
| | - Juliet R C Pulliam
- DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa
| |
Collapse
|
9
|
McMahon ME, Abbott A, Babayan Y, Carhart J, Chen CW, Debie E, Fu M, Hoaglund-Hyzer C, Lennard A, Li H, Mazzeo T, McCaig L, Pischel S, Qiu F, Stephens D, Timpano R, Webb D, Wolfe C, Woodlief K, Wu Y. Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies. AAPS J 2021; 23:107. [PMID: 34529169 DOI: 10.1208/s12248-021-00641-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Accepted: 08/20/2021] [Indexed: 11/30/2022] Open
Abstract
In consideration of the recent ICH Quality Discussion Group (QDG) recommended revision to the ICH series of stability guidelines, the IQ Consortium (International Consortium for Innovation and Quality in Pharmaceutical Development) Science- and Risk-based Stability Working Group conducted a comprehensive review of ICH Q1A, Q1B, Q1C, Q1D, Q1E, and Q5C to identify areas where the guidelines could be clarified, updated, and amended to reflect the potential knowledge gained from current risk-based predictive stability tools and to consider other science- and risk-based stability strategies in accordance with ICH Q8-12. The recommendations propose a holistic approach to stability understanding, utilizing historical data, prior knowledge, modeling, and a risk assessment process to expand the concept of what could be included (or would be acceptable) in the core stability data package, including type and amount of stability evidence, assignment of retest period and shelf-life for a new product, and assessment of the impact of post-approval changes.
Collapse
Affiliation(s)
- Megan E McMahon
- Pfizer Inc., Eastern Point Road, Groton, Connecticut, 06340, USA.
| | - Alexander Abbott
- Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, UK
| | - Yelizaveta Babayan
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | - Jenny Carhart
- Takeda Pharmaceuticals Inc., 40 Landsdowne Street, Cambridge, Massachusetts, 02139, USA
| | - Chi-Wan Chen
- Pfizer Inc. (Retired), 8455 Colesville Rd, Silver Spring, Maryland, 20910, USA
| | - Elke Debie
- Janssen R&D A Division of Janssen Pharmaceutica NV, Turnhoutseweg 302340, Beerse, Belgium
| | - Mingkun Fu
- Sunovion Pharmaceutical Inc., 84 Waterford Drive, Marlborough, Massachusetts, 01752, USA
| | | | - Andrew Lennard
- Amgen Ltd., 1 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
| | - Hanlin Li
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts, 02210, USA
| | - Tony Mazzeo
- Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey, 08903, USA
| | - Lori McCaig
- Seagen Inc., 21823 30th Drive SE, Bothell, Washington, 98021, USA
| | - Sylvine Pischel
- GlaxoSmithKline, Great West Road, Brentford, TW8 9GS, Middlesex, UK
| | - Fenghe Qiu
- Boehringer Ingelheim, 900 Ridgebury Road, Ridgefield, Connecticut, 06877, USA
| | - Dennis Stephens
- AbbVie, 1 N Waukegan Road, North Chicago, Illinois, 60064, USA
| | - Robert Timpano
- Pfizer Inc., Eastern Point Road, Groton, Connecticut, 06340, USA
| | - Debra Webb
- AbbVie, 1 N Waukegan Road, North Chicago, Illinois, 60064, USA
| | - Chad Wolfe
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | | | - Yan Wu
- , Merck & Co., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| |
Collapse
|
10
|
Ross JC, Saidu Y, Nzuobontane D, Voukings MZ, Embrey SR. Application of the remaining vaccine vial monitor life calculation to field temperature monitoring data to improve visibility into cold chain equipment performance. Vaccine 2020; 38:7683-7687. [PMID: 33082013 DOI: 10.1016/j.vaccine.2020.09.078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 09/22/2020] [Accepted: 09/26/2020] [Indexed: 10/23/2022]
Abstract
Vaccine Vial Monitors (VVM) are used to estimate if a vaccine has been exposed to excessive hot temperatures. This endpoint measurement is useful in determining if a vaccine is safe to be administered to a patient, but it does not pinpoint where in the cold chain a vaccine was exposed to excessive heat. With the expansion and technological advancement of cold chain equipment temperature monitoring, it is now possible to remotely estimate VVM status as a vaccine moves through the cold chain. In the present study, we examine the application of the mathematical principles backing VVMs on real, continuous, temperature monitoring data in Africa. Results suggest that exposure to short bursts of hot temperature or long power outages may still allow for safe distribution of affected vaccines. The remaining VVM life calculation could improve managerial visibility into cold chain equipment performance allowing for better data-driven planning and maintenance decisions.
Collapse
Affiliation(s)
- Jesse C Ross
- Nexleaf Analytics, 1964 Westwood Blvd. Suite 410, Los Angeles, CA 90025, United States.
| | - Yauba Saidu
- Clinton Health Access Initiative, Yaounde, Cameroon.
| | | | | | - Sally R Embrey
- Nexleaf Analytics, 1964 Westwood Blvd. Suite 410, Los Angeles, CA 90025, United States.
| |
Collapse
|
11
|
Clénet D, Hourquet V, Woinet B, Ponceblanc H, Vangelisti M. A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate. Eur J Pharm Biopharm 2019; 142:334-343. [PMID: 31306751 PMCID: PMC6727866 DOI: 10.1016/j.ejpb.2019.07.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 07/04/2019] [Accepted: 07/06/2019] [Indexed: 11/25/2022]
Abstract
The stability of live-attenuated viruses is very challenging due to thermal sensitivity; therefore, solid form is usually required (often freeze-dried products). Micropellet technology is a lyophilization technology that has the potential to provide greater flexibility in the presentation of a given vaccine particularly in multi-dose format or in combination of different vaccines. As a novel vaccine alternative process, this spray freeze-dried (SFD) micropellet technology was evaluated using as a model a yellow fever virus produced in Vero cells (vYF). Screening of excipients was performed in order to optimize physico-chemical properties of the micropellets. Sugar/polymer-based formulations induced high glass transition temperature (Tg), adequate breaking force and attrition resistance of the SFD micropellets. These mechanical parameters and their stability are of considerable importance for the storage, the transport but also the filling process of the SFD micropellets. By adding excipients required to best preserve virus infectivity, an optimal sugar/polymer-based formulation was selected to build micropellets containing vYF. Monodisperse and dried micropellets with a diameter of about 530 µm were obtained, exhibiting similar potency to conventional freeze-dried product in terms of vYF infectious titer when both solid forms were kept under refrigerated conditions (2–8 °C). Comparable kinetics of degradation were observed for vYF formulated in micropellets or as conventional freeze-dried product during an accelerated stability study using incubations at 25 °C and 37 °C over several weeks. The results from this investigation demonstrate the ability to formulate live-attenuated viruses in micropellets. Pharmaceutical applications of this novel vaccine solid form are discussed.
Collapse
Affiliation(s)
- Didier Clénet
- Bioprocess R&D Department, Sanofi Pasteur, Marcy l'Etoile, France.
| | | | | | - Hervé Ponceblanc
- Analytical Sciences BIEM, Sanofi Pasteur, Neuville s/Saône, France
| | - Manuel Vangelisti
- R&D Global Projects Strategy and Execution, Sanofi Pasteur, Marcy l'Etoile, France
| |
Collapse
|